Abstract The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant chemotherapy and/or endocrine therapy and were randomised to receive neither additional treatment nor intravenous ZOL 4 mg. ZOL was administered after each chemotherapy cycle to exploit potential sequence-dependent synergy. ZOL was continued for 60 months post-randomisation (six doses in the first 6 months, eight doses in the following 24 months and five doses in the final 30 months). Serious (SAE) and non-serious adverse event (AE) data generated during the first 36 months on study were analysed for the safety population. 3,360 patients were recruited to the AZURE trial. The safety population comprised 3,340 patients (ZOL 1,665; control 1,675). The addition of ZOL to standard treatment did not significantly impact on chemotherapy delivery. SAE were similar in both treatment arms. No significant safety differences were seen apart from the occurrence of osteonecrosis of the jaw (ONJ) in the ZOL group (11 confirmed cases; 0.7%; 95% confidence interval 0.3-1.1%). ZOL in the adjuvant setting is well tolerated, and can be safely administered in addition to adjuvant therapy including chemotherapy. The adverse events were consistent with the known safety profile of ZOL, with a low incidence of ONJ.
Introduction
Despite significant advances in the adjuvant treatment of early breast cancer, the disease still results in approximately 410,000 global deaths each year [1, 2] . The 'AZURE' phase III trial is investigating whether addition of the bisphosphonate zoledronic acid (ZOL) to standard adjuvant treatments further improves the disease-free survival (DFS) of stage II/III breast cancer patients.
Widely used in benign and malignant bone diseases, the bisphosphonates have become familiar agents in routine clinical practice. ZOL is a bisphosphonate that efficiently inhibits osteoclast function, resulting in profound inhibition of bone resorption. In addition, a body of evidence is emerging that describes anti-tumour activity of bisphosphonates, including evidence of synergy with cytotoxic agents [3, 4] . In the clinical setting, a phase III study in 1,800 pre-menopausal women with oestrogen receptorpositive disease, demonstrated a 36% reduction in the risk of developing recurrent disease from the addition of ZOL to endocrine therapy [5] .
Bisphosphonates are generally well tolerated, with renal dysfunction [6] and osteonecrosis of the jaw (ONJ) the only clinically important toxicities associated with their use [7, 8] . However, combining ZOL with chemotherapy has the potential for enhanced toxicity, especially if there is a synergistic interaction with chemotherapy on normal tissues. Safety evaluation within the AZURE trial is the ideal opportunity to assess this. Here, we report the largest data set evaluating safety of ZOL outside the metastatic setting and the first analysis at this intensive dosing schedule addressing specific adverse events of note including renal and cardiovascular effects, outcomes of pregnancies and ONJ as well as potential effects on chemotherapy related side-effects such as neutropaenic fever and mucositis.
Patients and methods
AZURE is a multi-centre, international, open label, randomised parallel group trial (ISRCTN79831382). Figure 1 shows the trial schema. Eligible patients were women with stage II/III breast cancer scheduled to receive (neo)adjuvant chemotherapy and/or endocrine therapy, of ECOG performance status 0-1 and aged C18 years. Patients with abnormalities of bone metabolism, prior treatment with bisphosphonates within 1 year, or evidence of renal impairment (serum creatinine [ 1.5 times upper limit of normal) were excluded. All patients gave written informed consent before study entry.
ZOL was administered at a dose of 4 mg intravenous (i.v.) over 15 min. Dose reductions and interruptions for renal impairment (calculated creatinine clearance \ 60 ml/ min) were as specified by the current prescribing information. Chemotherapy-or endocrine-related toxicities were handled according to local protocols.
Baseline and safety assessments
Safety assessments consisted of recording and immediate reporting of all serious adverse events (SAEs), recording of adverse events (AEs) potentially related to either treatment or the disease process using common toxicity criteria (CTC) [9] , regular monitoring of blood chemistry and physical examinations. AEs considered unrelated to the study drug, cancer treatment(s) or the disease process were Fig. 1 Trial schema. 'Standard therapy refers to any locally approved cytotoxic chemotherapeutic or endocrine agents not routinely collected. SAEs were described according to duration, seriousness, relationship to study drug or underlying cancer and any action taken. Serum creatinine was measured at baseline and every treatment visit for patients receiving ZOL. In the control arm, renal monitoring was required at baseline, 3 and 6 months, and then at the same frequency as the ZOL arm.
SAEs were sent to the Clinical Trials Research Unit (CTRU), Leeds, whilst non-serious AE data were sent to the local participating clinical trials units. All safety data were overseen by an independent Data Monitoring and Ethics Committee. In addition, a Trial Steering Committee (TSC) was established to provide overall supervision of the trial including patient safety.
In February 2004, following the emergence of a potential link between ONJ and bisphosphonates [10] , the patient information sheet was revised to address this possible risk and consent was re-obtained for those patients already enrolled. The protocol was amended in July 2005 to exclude patients with significant active dental problems or recent jaw surgery. In May 2006, dental hygiene advice was distributed to all patients, and guidance on the diagnosis, prevention and treatment of ONJ based on emerging clinical guidelines provided to all investigators. Investigators were requested to report all possible cases of ONJ as serious adverse events for central review. This triggered a request for additional detailed information on clinical features, prior dental interventions, imaging and biopsy results for central review. A diagnosis of ONJ was 'confirmed if the description conformed to the definition stipulated in the guidance documents from the American Association of Oro-Maxillary Surgeons (AAOMS) [11] and the American Association for Bone and Mineral Research (ASBMR) [8] . All other cases reported by investigators were classified as 'possible ONJ.
Statistical methods
Patients were stratified by participating centre and randomised using minimisation to ensure lymph node involvement, and tumour stage, ER status, type of adjuvant systemic therapy, use of statins and menopausal status were similar in both arms.
Two time periods have been evaluated: (i) randomisation to 6 months to capture safety information during (neo)adjuvant chemotherapy and (ii) 6 months to 3 years to represent the follow-up period when ZOL was given alone in the treatment arm (± endocrine treatments according to ER status or trastuzumab for HER2 positive patients recruited during 2005/6).
ONJ rates were calculated using cumulative incidence functions, where deaths without diagnosis of ONJ were considered competing-risk events, and compared using the log-rank test. Patients without evidence of ONJ were censored at date of death or the last date they were known to be alive. Hypothesis testing was at the 5% significance level (2-sided) and performed using SAS version 9.2 (SAS Institute Inc., Cary, NC).
Safety population
This safety analysis includes data from the first 3 years of follow up from randomisation for which we have complete data in approximately 95% of patients. Patients are included in the treatment group to which they were randomised. In the treatment arm, patients who did not receive any ZOL have been excluded from the safety population. Control patients who received ZOL at a later visit (regardless of the reason) have been censored at the time of first administration. Patients who developed distant metastasis have been censored at the time this was confirmed.
Results

Patient population
The AZURE trial SAEs were reported amongst 22.0% (352/1,600) and 24.5% (389/1,590) of patients in the control and ZOL groups respectively (Table 3) . 1,007 SAEs were reported in total (control 480 vs. ZOL 527). Amongst patients receiving ZOL, the SAE was suspected to be related to ZOL in 14 (2.7%): pyrexia (n = 7), anaphylactic reaction (n = 2), ONJ (n = 1), pain (n = 1), vomiting (n = 1), iritis (n = 1) and elevated creatinine (n = 1). The most common SAE was neutropenic sepsis (control 9.3% vs. ZOL 9.4%). All other SAEs occurred in less than 3% of patients.
Chemotherapy duration and dose reductions
The median duration of chemotherapy delivery was similar in both groups (control 4.0 months vs. ZOL 3.9 months). Chemotherapy dose reductions were required in 230/1,600 (14.4%) control and 209/1,590 (13.1%) ZOL patients. The duration of chemotherapy and the number of dose reductions were similar in both the neoadjuvant and post-operative settings (data not shown). , and remained similar to baseline levels in both groups. During the adjuvant chemotherapy phase, renal failure was reported as an SAE in three cases (control 1 vs. ZOL 2). The two cases in the ZOL group were reported as not suspected to be related to the bisphosphonate. In addition, increases in serum creatinine of any CTC grade were uncommon (control 0.5% vs. ZOL 0.4%). ZOL was delayed in accordance with the product characteristics in seven patients and/or the dose reduced at the clinician's discretion in six patients due to a decline in calculated creatinine clearance. No data from site (n=3) Fig. 2 CONSORT diagram of patient disposition in trial within the control arm were recorded as 'chemotherapy toxicity (n = 4), pneumonia (n = 1), septicaemia (n = 1), thrombo-embolic disease (n = 1) and suicide (n = 1). Primary causes of death within the ZOL arm were recorded as 'breast cancer related (n = 1), 'chemotherapy toxicity (n = 1), 'pulmonary embolus' (n = 1), 'cardiac failure' (n = 1) and 'unknown' (n = 1).
Dental adverse events
Post chemotherapy phase (6 months-3 years)
During this period, ZOL continued to be administered every 3 months from months 9 to 30 on study, and then every 6 months until 60 months. During this phase, no patient received chemotherapy. Trastuzumab and/or endocrine therapy were given as per local guidelines.
Overall safety profile
Overall, the administration of ZOL was well tolerated and without significant additional toxicity. 
Effects on renal function
Two cases (\0.1%) of renal failure were described as SAEs, one case in each arm. The case of renal failure in the patient receiving ZOL occurred in a 44-year-old patient following 12 doses of ZOL, 1,065 days from randomisation. She had acute renal failure and hypercalcaemia, not suspected to be related to ZOL.
Other adverse events of interest
Osteonecrosis of the jaw 11 patients with confirmed ONJ (0.7%, 95% confidence interval (CI) 0.3-1.2%) have been reported in the ZOL arm (one during chemotherapy, 10 in follow-up period), whilst no cases have been reported in the control arm (log-rank test = 10.9808, degrees of freedom = 1, P = 0.0009). Cases were confirmed according to published definitions [8, 11] . In five patients, ONJ affected more than one site. All were suspected to be related to treatment with ZOL ( Table 5 ). An additional four cases in the ZOL arm were reported by the investigator as possible ONJ did not meet the diagnostic criteria for a definitive diagnosis. The case during adjuvant chemotherapy followed a dental abscess requiring extraction after the first ZOL infusion. Affecting both the mandible and maxilla, the condition was confirmed after the sixth infusion when ZOL was discontinued. Following resolution of ONJ a year later, ZOL was reintroduced without any subsequent recurrence of ONJ.
The median number of ZOL 4 mg infusions before confirmation of ONJ was 10 (range 6-14). The median age of patients at time of confirmation of ONJ was 54 years (range 39-72). Nine cases underwent a dental extraction before the diagnosis of ONJ. The median time from randomisation to confirmation of ONJ was 746 days (range 238-1,029). Outcomes of cases to date are as follows: 'completely recovered' n = 4; 'recovered with sequelae' n = 2; 'improving' n = 2; 'condition present and unchanged' n = 3.
In addition, two patients in the ZOL group developed avascular necrosis (AVN) of the femoral head (one bilateral). Both AVN patients had received chemotherapy and corticosteroids in the preceding 3 months. In both cases, ZOL was discontinued, although a causal association could not be established. ZOL, and differences between groups did not reach statistical significance.
Cardiovascular events
Pregnancies whilst on study 15 patients from the defined safety population became pregnant (control 6 vs. ZOL 9). Two patients (one from each arm) became pregnant twice, resulting in a total of 17 pregnancies. Nine of these pregnancies were aborted (six planned terminations, three spontaneous abortions), seven resulted in live births (control 3, ZOL 4), whilst in the remaining case the outcome of the pregnancy is not known. Of the four ZOL treated patients who had a live birth, the first had 12 doses and stopped treatment 11 months before delivery, the second had 11 doses, stopping 18 months before delivery, the third had 11 doses, stopping 15 months before delivery, whilst the fourth received 10 doses but the time between her last ZOL treatment cannot be determined.
No overt abnormalities were seen at delivery or have been subsequently reported in any of the live births. 
New primary cancers
Discussion
We report the largest safety analysis of ZOL given on an intensive schedule in the non-metastatic cancer setting. This extensive body of data from a randomised trial confirms that ZOL can be given safely in combination with chemotherapy, without significant impact on toxicity of chemotherapy. Although not formally calculated, the similar duration of chemotherapy and frequency of dose reductions indicate that ZOL had no clinically relevant impact on the dose intensity of chemotherapy. This is the first study to have reported on the use of ZOL in the adjuvant setting combined with chemotherapy. The ABCSG-12, ZOFAST, Z-FAST, and EZO-FAST studies all evaluated ZOL alongside hormonal therapy in the adjuvant setting, and with a less-intensive six-monthly schedule [5, [12] [13] [14] . As in these trials, with the usual advice given to patients on minimising the effects of the acute phase reaction and renal monitoring [15] , the toxicity impact of ZOL was minimal with the exception of a low frequency of ONJ. At the time of data lock, all the patients had completed at least 3 years of treatment, and we were in receipt of[95% of data related to these treatment. With the possible exception of ONJ, for which patients remain at risk throughout years 4 and 5 on treatment (and potentially beyond completion of treatment), further additional safety signals of note are unlikely to emerge now that treatment administration is on a 6 monthly frequency. However, this will be fully evaluated in future reports as the study matures.
The association between bisphosphonate use and ONJ was first described in 2003 [10] . Causation has been difficult to prove and the pathogenesis of the condition uncertain and probably multifactorial. ONJ is also associated with the use of denosumab [16] , suggesting that the suppression of osteoclast numbers and function has a central role in the pathophysiology of this condition. However, ONJ has also been reported in association with angiogenesis inhibitors such as bevacizumab [17] , supporting the notion of multiple aetiological factors. The incidence of ONJ amongst patients receiving oral bisphosphonate for osteoporosis is very low (\1 in 10,000), and substantially less than is seen with intravenous bisphosphonates for advanced malignancy [11] . In the metastatic setting, it has been concluded that dental interventions, disease and treatment related immune suppression, duration of exposure and number of bisphosphonate infusions are the most significant risk factors for development of the condition [8, 11] . The incidence of ONJ in metastatic cancer has been estimated at 0.8-12% (2.9-5.3% in breast cancer) [8, 11, 18, 19] , with an average of approximately 1% per year on treatment [20] .
In AZURE, the low frequency of ONJ (0.7%, 95% CI 0.3-1.1%)) is likely to reflect less immune suppression than that occurs in the metastatic setting, limited exposure to chemotherapy, careful monitoring, and conservative dental intervention whenever possible, plus the less-intensive schedule used once the initial 6 months' chemotherapy phase was completed. However, the frequency of ONJ appears more than has been reported with six-monthly ZOL in the ABCSG-12, ZOFAST, Z-FAST and EZO-FAST studies. Here, only two possible cases of ONJ have been reported out of [4,000 patients [5, [12] [13] [14] .
In advanced cancer, renal effects related to dose, infusion duration and total number of infusions of ZOL may be seen [6] . It is likely that in the advanced setting, nephrotoxicity is multifactorial, compounded by advancing cancer, co-morbidities and other drugs [21] . However, our results indicate that ZOL given in the adjuvant setting for patients with early breast cancer has no significant impact on renal function.
The initial reports of atrial fibrillation (AF) in relation to ZOL use came from outside the cancer setting. In the HORIZON study of postmenopausal women with osteoporosis, serious AF (new or recurrent) was seen in 1.3% of patients receiving ZOL compared to 0.5% in the control arm [22] . No clear association between bisphosphonates and AF could be identified in subsequent safety reviews [23, 24] . However, a recent claim-based analysis of 6,857 cancer patients aged [65 and receiving bisphosphonates identified an approximate 30% increased risk for both AF and supraventricular tachycardias (SVT) when compared with matched cancer controls [25] . In our study, it is possible that some non-serious episodes of AF or other supraventricular tachycardias were not reported as these were not adverse events of interest until the initial reports in 2007. However, our findings do not suggest any clinically relevant excess risk for AF with use of ZOL in the adjuvant setting. A numerical excess of cardiovascular SAE was reported, but there was no significant excess of any individual cardiovascular event in the ZOL arm, and very similar numbers of arrhythmias.
Bisphosphonates have been shown to cross the placenta in pre-clinical studies, raising concern for birth defects [26, 27] . The few case reports of bisphosphonate administration during pregnancy are, however, reassuring [28, 29] . Of the pregnancies which went to term in the ZOL arm of AZURE, all were planned, and therefore ZOL was stopped before conception. Despite this, there remains the concern that, owing to the long retention time of bisphosphonates in bone, foetal exposure may occur even if the drug is stopped long before conception [29] . A recent study of pre-pregnancy or early pregnancy exposure to alendronate (n = 20) reported no major malformations and five spontaneous abortions [30] . In another series of patients who received bisphosphonates (not ZOL) within 12 months of conception or during the first trimester of pregnancy (n = 21), no increased risk of birth defects was seen [29] . We could not find any published reports regarding exposure to ZOL and pregnancy outcome, but concerns regarding foetal development remain because of the potency and long offset duration of ZOL [31] .
Conclusion
This safety analysis expands our understanding of the tolerability and risks of ZOL in the adjuvant setting and shows that it can be administered safely without compromising chemotherapy delivery. A low incidence of ONJ was observed. If the efficacy of adjuvant ZOL is confirmed and does become part of standard adjuvant treatment, then this report is reassuring and predicts for a favourable riskbenefit ratio.
